DOI: https://doi.org/10.14710/jbtr.v8i2.15318

Comparison of Testosterone Undecanoate (TU) and Testosterone Enanthate (TE) with Combination of Depot Medroxyprogesterone Acetate (DMPA) on Spermatogenic Cells in Men

Faculty of Medicine, Universitas Indonesia, Indonesia

Received: 25 Jul 2022; Revised: 12 Aug 2022; Accepted: 22 Aug 2022; Available online: 31 Aug 2022; Published: 31 Aug 2022.
Open Access Copyright (c) 2022 Journal of Biomedicine and Translational Research
Creative Commons License This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

Citation Format:
Abstract

Introduction: Male hormonal contraception known as safe, effective, and reversible
contraception. World Health Organization (WHO) multicentre study has been conducted a
clinical study administrating of testosterone regimens and progestin to male with a remarkable
result. Azoospermia or severe oligozoospermia occurred in men with injection of Testosterone
Enanthate (TE) and Depot Medroxyprogesterone Acetate (DMPA) as well as Testosterone
Undecanoate (TU) and DMPA for a longer period. Decreasing gonadotropin as well as
testosterone could lead to the amount of spermatogenic cells population declining by suppressing
the development of many kinds of cells. This narrative review was to compare how
spermatogenic suppression in TE and TU with Combination of DMPA. Method: We are
randomly select article or journal from several databases and individual journal in certain
keywords. The keyword used were : (male hormonal contraception) OR (regimen testosterone))
AND (progestin) OR (DMPA) OR (Testosterone enanthate) OR (Testosterone undecanoate) OR
(male hormonal contraception combination)) AND (DMPA to spermatogenic cells) OR
(Testosterone and DMPA to germ cell development)). After initial searching from databases and
individual journal website, 16 scientific articles or journals selected for the review. Result: The
result indicated that injection of TE and DMPA had suppressed spermatogenesis, might not
suppressed sperm production for a longer period but the decreasing in type B spermatogonia
until pachytene spermatocyte did occur. On the other hand, injection of TU and DMPA could
maintain the suppression of sperm production for a longer period due to sustainable higher serum
MPA with combination to even longer-acting TU would have more profound effect for that.
Conclusion: It was known that combination of TU and DMPA might have better suppression on
sperm production than TE and DMPA, otherwise further research needs to be obtained from the
combination of TU and DMPA on spermatogenic development and the association with
intratesticular testosterone.

Fulltext View|Download
Keywords: Male hormonal contraception, Gonadotropin, Testosterone, Testosterone Enanthate and DMPA, Testosterone Undecanoate and DMPA, Spermatogenic suppression.
Funding: Universitas Indonesia

Article Metrics:

Article Info
Section: Review Articles
Language : EN
Recent articles
The Effectiveness of Ethanol Extract of Neem Leaf (Azadirachta indica) Mouthwash Against The Growth of Streptococcus sp. Correlation between Interleukin-17 Levels with C-Reactive Protein and Neutrophil Lymphocyte Ratio in Sepsis The Effect of Duration of Administration and Discontinuation of Fluorometholone Eye Drops on The Trabecular Meshwork Comparison of Testosterone Undecanoate (TU) and Testosterone Enanthate (TE) with Combination of Depot Medroxyprogesterone Acetate (DMPA) on Spermatogenic Cells in Men More recent articles
  1. Thirumalai A, Page ST. Recent Developments in Male Contraception. Drugs. 2019;79(1):11-20. DOI : 10.1007/s40265-018-1038-8
  2. Badan Pusat Statistik. Hasil Sensus Penduduk 2020 [Internet]. 2020. Available From:
  3. Https://Www.Bps.Go.Id/Pressrelease/2021/01/21/1854/Hasil-Sensus-Penduduk-2020.Html
  4. Badan Pusat Statistik. Laju Pertumbuhan Penduduk Menurut Provinsi [Internet]. 2017. Available From: Https://Www.Bps.Go.Id/
  5. Jing H. Chao STP. The Current State of Male Hormonal Contraception. Phar & Ther. 2016;163:109-117. DOI : http://dx.doi.org/10.1016/j.pharmthera.2016.03.012
  6. Wang C, Festin MP, Swerdloff RS. Male hormonal contraception: where are we now? Curr Obstet Gynecol Rep. 2016;5:38-47. DOI : 10.1007/s13669-016-0140-8
  7. Medical eligibility criteria for contraceptive use, Sexual and reproductive Health, 5 thedition, 2015 World Health Org. [Internet] Available from:
  8. http://www.who.int/reproductivehealth/publications/family_planning/Ex-Summ-MEC-
  9. /en. 23 Aug 2015
  10. Midoen YH, Dita RA, Dwi AS, Hans JF. Finding the Minimal Effective Dose of a Combination of Depot Medroxyprogesterone Acetate and Javanese Long Pepper for Male Contraception on Testicular Fertility Parameters in Male Sprague Dawley Rats. Biomed & Pharmacol J. 2017;10(2):725-37. DOI : http://dx.doi.org/10.13005/bpj/1162
  11. Thirumalai A, Page ST. Male Hormonal Contraception. Ann Rev Med. 2020;71:8.1-8.15
  12. DOI : https://doi.org/10.1146/annurev-med-042418-010947
  13. Giulia G, Meriggiola MC Update on Male Hormonal Contraception. Ther Adv Endocrinol Metab. 2019;10:1-9. DOI :10.1177/2042018819834866
  14. Ilyas S, Silvia WL, Nukman M et al. Induction of Rat Germ Cell Apoptosis by Testosterone Undecanoate and Depot Medroxyprogesterone Acetate and Correlatiom of Apoptotic Cells with Sperm Concentration. Acta Medica Indonesiana. 2017;45(1):32-37
  15. Mclachlan RI. Liza O. Peter GS et al. Effects Of Testosterone Plus Medroxyprogesterone Acetate On Semen Quality, Reproductive Hormones, And Germ Cell Populations In Normal Young Men. J Clin Endocrinol Metab. 2002;87(2):546-56. DOI : 10.1210/jcem.87.2.8231
  16. Kelsey TW, Amy M, Rod TM et al. A Normative Model of Serum Inhibin B in Young Males. PLoS ONE. 2016;11(4):e0153843. DOI : 10.1371/journal.pone.0153843
  17. O’Donnell L, Robert IM. Testosterone: Action, Deficiency, Substitution. UK: Cambrigde University Press. 2012
  18. Cheng YC, Dolores DM. The Blood-Testis Barrier and Its Implication for Male Contraception. Pharmacol Rev. 2012;64:16-64. DOI : 10.1124/pr.110.002790
  19. Paul KMW. Male Contraception History and Development. Urol Clin N Am. 2014;41:145-61. DOI : 10.1016/j.ucl.2013.08.012
  20. Behre HM, Eberhard N. Testosterone preparations for clinical use in males. . In Testosterone, Action, Deficiency,Substitution. Eds E Nieschlag & HM Behre, UK: Cambridge University Press. 2011. 309-330 pp
  21. Yuen F, Brian TN, Ronald SS et al. Continuing the search for hormonal male contraceptive. Best Prac & Res Clin Obs and Gyn. 2020; 66:83-94. DOI : 10.1016/j.bpobgyn.2020.02.003
  22. Chao J, Stephanie TP, Richard AA. Male Contraception. Best Prac & Res Clin Obs and Gyn. 2014:1-13. DOI : http://dx.doi.org/10.1016/j.bpobgyn.2014.05.008
  23. Long JE, Min SL, Diana LB. Update on Novel Hormonal and Nonhormonal Male Contraceptive Development. The J of Clin Endocrinol & Metab. 2021;106(6):e2381-e92. DOI :10.1210/clinem/dgab034
  24. Silvia WL, Seruni TK, Yurnadi HM, Andon H, Tjahjo DT, Reny I. An Update Of Male Contraception : A Review Of Cellular Perspective. J Of Glo Pharma Tech. 2019;11(1):219-29
  25. Gu YQ, Ding-Zhi M, Xing-Hai W et al. Male Hormonal Contraception: Effects Of Injections Of Testosterone Undecanoate And Depot Medroxyprogesterone Acetate At Eight-Week Intervals In Chinese Men. J Clin Endocrinol Metab. 2004;89(5):2254-62. DOI: 10.1210/jc.2003-031307

Last update:

No citation recorded.

Last update:

No citation recorded.